Acción CGEM CULLINAN THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Cullinan Therapeutics, Inc.

Acciones

CGEM

US2300311063

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 26/06/2024 		Varia. Cinco días. Varia. 1 de enero.
16,5 USD +0,49 % Gráfico intradía de Cullinan Therapeutics, Inc. -1,84 % +61,92 %
02/06 Transcript : Cullinan Therapeutics, Inc. - Special Call
01/06 Cullinan Therapeutics, Inc. Anuncia datos iniciales positivos del estudio pivotal de fase 2b Rezil1 de zipalertinib CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib
Cullinan Therapeutics : Full Pipeline Overview
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cullinan Therapeutics, Inc. Announces Board Changes
Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing
Cullinan Therapeutics, Inc. announced that it has received $280.000024 million in funding from a group of investors
Cullinan Therapeutics Appoints Mary Kay Fenton as CFO
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Cullinan Oncology : Therapeutics Corporate Update
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción CGEM
  4. Noticias Cullinan Therapeutics, Inc.
  5. Otros idiomas